FDA greenlights Hunter syndrome drug after rare disease rejections

The FDA’s approval of Denali Therapeutics’ Hunter syndrome drug marks a rare bright spot in a year where rare disease therapies have faced unusually high rejection rates. The decision, announced this week, grants patients with this lysosomal storage disorder a new treatment option—but one that arrives with the usual caveats of early-stage regulatory approvals.

Hunter syndrome, or mucopolysaccharidosis type II, affects fewer than 2,000 people globally, leaving patients with limited therapeutic choices. Denali’s enzyme replacement therapy, now cleared under the brand name Surnazyme, targets the underlying enzymatic deficiency. Yet while the approval is confirmed, its clinical impact remains to be seen.

The FDA’s move is notable precisely because it bucks a recent trend: since 2023, the agency has rejected at least four rare disease drugs over efficacy or safety concerns. Denali’s success suggests either a shift in regulatory flexibility—or simply a stronger dataset. The company’s Phase 3 trial, while meeting its primary endpoint, enrolled just 63 patients, a sample size that limits broader conclusions.

This isn’t a cure. It’s a step—one that patients and clinicians will watch closely for real-world performance.

For families navigating Hunter syndrome, the approval offers immediate, if incremental, relief. Current treatments focus on managing symptoms; Surnazyme may slow disease progression but won’t reverse existing damage. The label’s fine print underscores this: improvements in biomarkers don’t always translate to tangible quality-of-life gains.

The regulatory path here also highlights a tension. The FDA’s rare disease division has faced criticism for inconsistent standards, with some arguing it’s too rigid, others too lenient. Denali’s win could signal a recalibration—or an outlier. Without long-term data, the risk of overpromising looms. Early adopters will effectively serve as a post-market study cohort.

What’s missing? Durability data. Most trials track patients for 12–24 months; Hunter syndrome progresses over decades. And while the drug’s mechanism is biologically plausible, real-world adherence and side effects (e.g., infusion reactions) may temper enthusiasm.

For now, the approval is a data point, not a precedent. The rare disease community will parse whether this reflects a broader FDA softening—or just one therapy clearing a high bar.